Literature DB >> 18390943

Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults.

Laurence Y Katz1, Anita L Kozyrskyj, Heather J Prior, Murray W Enns, Brian J Cox, Jitender Sareen.   

Abstract

BACKGROUND: Regulatory bodies worldwide, including Health Canada, have issued warnings about prescribing antidepressants to children and adolescents. We sought to determine whether the Health Canada warning had the desired effects on prescribing patterns and outcomes and whether it had any unintended health consequences.
METHODS: We examined data from prescription and health care databases representing more than 265 000 children, adolescents and young adults annually to determine changes in the rates of antidepressant prescription, use of health services and outcomes in these populations in the 9 years before and the 2 years after the Health Canada warning. We also examined the data for unintended changes in these rates among patients with anxiety disorders. We used young adults as the comparison group because they were not targeted by the warning.
RESULTS: Following the warning, the rate of antidepressant prescriptions decreased among children and adolescents (relative risk [RR] 0.86, 95% confidence interval [CI] 0.81-0.91) and among young adults (RR 0.90, 95% CI 0.86-0.93). Ambulatory visits because of depression decreased among children and adolescents (RR 0.90, 95% CI 0.85-0.96) and young adults (RR 0.91, 95% CI 0.87-0.96). The rate of completed suicides among children and adolescents rose significantly after the warning (RR 1.25, 95% CI 1.08-1.44; annual rate per 1000 = 0.04 before and 0.15 after the warning). There was no equivalent change in the rate of completed suicides among young adults (RR 1.01, 95% CI 0.93-1.10; annual rate per 1000 = 0.15 before and 0.22 after the warning). Among patients with an anxiety disorder, the prescription rates did not change among children and adolescents, except for a decrease in the use of selective serotonin reuptake inhibitors other than fluoxetine, but the rates among young adults changed similar to the pattern of changes in the overall prescribing of antidepressants. There was also a significant decrease in the rate of physician visits because of anxiety disorders among young adults after the warning.
INTERPRETATION: Health advisories and warnings issued by regulatory bodies may have unintended consequences on the provision of care, delivery of health services and clinical outcomes. Further efforts are required to ensure that health warnings do not result in unexpected harm.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18390943      PMCID: PMC2276558          DOI: 10.1503/cmaj.071265

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  23 in total

1.  Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs.

Authors:  Robert J Valuck; Anne M Libby; Heather D Orton; Elaine H Morrato; Richard Allen; Ross J Baldessarini
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

2.  The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses.

Authors:  Andrew C Leon
Journal:  Am J Psychiatry       Date:  2007-12       Impact factor: 18.112

3.  The FDA pediatric advisories and changes in diagnosis and treatment of pediatric depression.

Authors:  Cynthia R Pfeffer
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

4.  Modern statistical techniques for the analysis of longitudinal data in biomedical research.

Authors:  L J Edwards
Journal:  Pediatr Pulmonol       Date:  2000-10

5.  Decrease in antibiotic use among children in the 1990s: not all antibiotics, not all children.

Authors:  Anita L Kozyrskyj; Anita G Carrie; Garey B Mazowita; Lisa M Lix; Terry P Klassen; Barbara J Law
Journal:  CMAJ       Date:  2004-07-20       Impact factor: 8.262

6.  Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.

Authors:  Robert D Gibbons; C Hendricks Brown; Kwan Hur; Sue M Marcus; Dulal K Bhaumik; Joëlle A Erkens; Ron M C Herings; J John Mann
Journal:  Am J Psychiatry       Date:  2007-09       Impact factor: 18.112

7.  What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?

Authors:  Nadia Barozzi; Susan E Tett
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-11       Impact factor: 2.890

8.  Effects of Food and Drug Administration warnings on antidepressant use in a national sample.

Authors:  Mark Olfson; Steven C Marcus; Benjamin G Druss
Journal:  Arch Gen Psychiatry       Date:  2008-01

9.  Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.

Authors:  Anne M Libby; David A Brent; Elaine H Morrato; Heather D Orton; Richard Allen; Robert J Valuck
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

10.  Effect of regulatory warnings on antidepressant prescribing for children and adolescents.

Authors:  Benji T Kurian; Wayne A Ray; Patrick G Arbogast; D Catherine Fuchs; Judith A Dudley; William O Cooper
Journal:  Arch Pediatr Adolesc Med       Date:  2007-07
View more
  45 in total

1.  A longitudinal epidemiological comparison of suicide and other causes of death in Italian children and adolescents.

Authors:  Maurizio Pompili; Monica Vichi; Diego De Leo; Cynthia Pfeffer; Paolo Girardi
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-02       Impact factor: 4.785

Review 2.  Impact of safety-related regulatory action on clinical practice: a systematic review.

Authors:  Sigrid Piening; Flora M Haaijer-Ruskamp; Jonie T N de Vries; Menno E van der Elst; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

3.  A Canadian Primary Care Sentinel Surveillance Network Study Evaluating Antidepressant Prescribing in Canada From 2006 to 2012.

Authors:  Rachael Morkem; David Barber; Tyler Williamson; Scott B Patten
Journal:  Can J Psychiatry       Date:  2015-12       Impact factor: 4.356

4.  Suicide and suicide attempts in children and adolescents in the child welfare system.

Authors:  Laurence Y Katz; Wendy Au; Deepa Singal; Marni Brownell; Noralou Roos; Patricia J Martens; Dan Chateau; Murray W Enns; Anita L Kozyrskyj; Jitender Sareen
Journal:  CMAJ       Date:  2011-10-17       Impact factor: 8.262

Review 5.  Concerns about health care warnings and their impact on prescribing behaviour.

Authors:  Laurence Y Katz
Journal:  CMAJ       Date:  2008-08-26       Impact factor: 8.262

6.  Author response.

Authors:  Raymond W Lam
Journal:  J Psychiatry Neurosci       Date:  2013-07       Impact factor: 6.186

7.  The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine.

Authors:  Pål Gjerden; Lars Slørdal; Jørgen G Bramness
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 8.  Screening for Depression in Pediatric Primary Care.

Authors:  Valerie L Forman-Hoffman; Meera Viswanathan
Journal:  Curr Psychiatry Rep       Date:  2018-07-23       Impact factor: 5.285

9.  Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.

Authors:  Antoine Pariente; Yohann Mansiaux; Ana Jarné; Francesco Salvo; Cécile Pageot; Julien Bezin; Andy Smith; Bernard Bégaud
Journal:  Eur J Clin Pharmacol       Date:  2017-09-02       Impact factor: 2.953

10.  The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.

Authors:  Darren Lam; Daniel A Gorman; Scott Patten; Tamara Pringsheim
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.